



**Supplemental Fig. S3.** Effect of finerenone compared to placebo on the risk for the cardiovascular composite endpoint according to the presence or absence of obesity at baseline. M-H, Mantel-Haenszel; CI, confidence interval; BMI, body mass index; FIDELIO-DKD, Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease; FIGARO-DKD, Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease.